Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Changing Paradigm for Sales and Marketing Growing Markets for High- and Low-priced Drugs -1-
June 16, 2008
- NEW PRODUCT／Daiichi Sankyo: Gracevit Tablets 50 mg, Fine Granules 10%
June 16, 2008
- SELF-MEDICATION NEWS IN BRIEF
June 16, 2008
- Changing Paradigm for Sales and Marketing Growing Markets for High- and Low-priced Drugs -2-
June 16, 2008
- STOP PRESS／Daiichi Sankyo to Acquire Majority of Ranbaxy Shares
June 16, 2008
- Daiichi Sankyo to Enter Oncology Field in Earnest by Acquiring U3 Pharma
June 16, 2008
- Lurasidone Holds Key to DSP's Success in Global Business Development: Mr Tada
June 16, 2008
- MORAb-003 Found Effective for Ovarian Cancer in PIIa Study: Eisai
June 16, 2008
- Kissei Licenses Selective SGLT-2 Inhibitors to GSK
June 16, 2008
- Incretin Therapy Highlighted at Annual Meeting of Japan Diabetes Society
June 16, 2008
- DSP Mounts Attack on Market for Antihypertensives with 7 Products with Different MOA
June 16, 2008
- 44th Annual Meeting of ASCO
June 16, 2008
- EPS to Embark on Chinese Business in Earnest
June 16, 2008
- R&D NEWS IN BRIEF
June 16, 2008
- CRO Business Pulls CMIC with 19.6% Increase in Sales
June 16, 2008
- TOPICS／27 Ex-Korosho Officials Employed by 17 Drug Makers
June 16, 2008
- BUSINESS NEWS IN BRIEF
June 16, 2008
- Banyu to Develop More Vaccines in Japan: New President Timney
June 16, 2008
- 3 Major Generics Makers Aim at Conservative Sales Targets for OTC Version of Amlodipine
June 16, 2008
- 34 Companies to Enter Market for Amlodipine with 70 Generic Products
June 16, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…